BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27338762)

  • 1. Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
    Shibata Y; Hara T; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Goto N; Nannya Y; Ito H; Kito Y; Miyazaki T; Takeuchi T; Saito K; Seishima M; Takami T; Moriwaki H; Shimizu M; Tsurumi H
    Hematol Oncol; 2017 Dec; 35(4):637-644. PubMed ID: 27338762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Yoshikawa T; Hara T; Tsurumi H; Goto N; Hoshi M; Kitagawa J; Kanemura N; Kasahara S; Ito H; Takemura M; Saito K; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2010 Apr; 84(4):304-9. PubMed ID: 19995374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
    Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
    Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
    Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.
    Kato A; Imai Y; Aoki K; Tabata S; Matsushita A; Hashimoto H; Takahashi T; Ishikawa T
    Ann Hematol; 2014 Jul; 93(7):1185-91. PubMed ID: 24526138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.
    Chihara D; Oki Y; Ine S; Yamamoto K; Kato H; Taji H; Kagami Y; Yatabe Y; Nakamura S; Morishima Y
    Leuk Lymphoma; 2009 Dec; 50(12):1999-2004. PubMed ID: 19860627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
    Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
    Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia.
    Mabuchi R; Hara T; Matsumoto T; Shibata Y; Nakamura N; Nakamura H; Kitagawa J; Kanemura N; Goto N; Shimizu M; Ito H; Yamamoto Y; Saito K; Moriwaki H; Tsurumi H
    Leuk Lymphoma; 2016; 57(1):92-8. PubMed ID: 25907424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
    Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
    Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral T-cell lymphoma--not otherwise specified.
    Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral T cell lymphoma, not otherwise specified with myelofibrosis: report of a case with review of the literature.
    Sekiguchi Y; Shirane S; Shimada A; Ichikawa K; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2015; 8(4):4186-203. PubMed ID: 26097612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
    Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
    J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients.
    Xu P; Yu D; Wang L; Shen Y; Shen Z; Zhao W
    Ann Hematol; 2015 Feb; 94(2):239-47. PubMed ID: 25193354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified.
    Li Q; Gao S; Ma J; Liu S; Yue Y; Chen L; Li H; Wang X; Li D; Cao Z; Zhao Z; Wang X; Yu Y; Zhang Y; Wang Y
    Leuk Res; 2018 Oct; 73():5-11. PubMed ID: 30172956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas.
    Kaito S; Kanemasa Y; Sasaki Y; Okuya T; Yamaguchi T; Funasaka C; Shimoyama T; Omuro Y; Hishima T; Maeda Y
    Int J Hematol; 2018 Apr; 107(4):451-459. PubMed ID: 29103138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.
    Huh SJ; Oh SY; Lee S; Lee JH; Kim SH; Lee GW; Kim SJ; Kim WS; Lee HS; Jo JC; Kim MJ; Kwon JH; Kim HJ
    Int J Hematol; 2019 Oct; 110(4):438-446. PubMed ID: 31250282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous peripheral T-cell lymphoma, not otherwise specified: A single-center prognostic analysis.
    Tolkachjov SN; Weenig RH; Comfere NI
    J Am Acad Dermatol; 2016 Nov; 75(5):992-999. PubMed ID: 27498959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.
    Bhatt VR; Giri S; Verma V; Manandhar S; Pathak R; Bociek RG; Vose JM; Armitage JO
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):373-8. PubMed ID: 27349764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.
    Niitsu N; Hayama M; Yoshino T; Nakamura S; Tamaru J; Nakamine H; Okamoto M
    Br J Haematol; 2011 Jun; 153(5):582-8. PubMed ID: 21492124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
    El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
    Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.